Browse > Article

Comparative Study of Anti-osteoporotic Agents in Postmenopausal Women  

Kim, Hee Sun (College of Pharmacy, Chung-Ang University)
Sohn, Minji (College of Pharmacy, Seoul National University)
Bang, Joon Seok (Graduate School of Clinical Pharmacy, Sookmyung Women's University)
Sohn, Uy Dong (College of Pharmacy, Chung-Ang University)
Publication Information
Korean Journal of Clinical Pharmacy / v.24, no.2, 2014 , pp. 98-105 More about this Journal
Abstract
Purpose: The aim of this study was to compare retrospectively the efficacy of anti-osteoporotic agents (RAL-Raloxifene 60 mg, ALD-weekly alendronate 70 mg, RSD-weekly risedronate 35 mg, AVD3-weekly alendronate 70 mg/vitamin $D_3$ 2800IU, IBD-quarterly IV ibandronate 3 mg/3 ml, ZLD-yearly IV zoledronate 5 mg/100 ml) in postmenopausal patients with osteoporosis or osteopenia. Method: This study retrospectively reviewed medical record and compared the lumbar spine BMD percentage changes of each medicine group one year later from the baseline. 209 patients (27, 50, 60, 30, 35, and 7 patients in RAL, ALD, RSD, AVD3, IBD, and ZLD groups, respectively) are within the inclusion criteria for the study. Results: From baseline to month 12, lumbar spine BMD increased significantly larger with bisphosphonate groups, compared to SERM (p < 0.05). In all bisphosphonate groups, the lumbar spine BMD were increased significantly from baseline. Of the bisphosphonates, the changes from baseline in BMD of IV bisphosphonates were more larger than those of oral bisphosphonates, and yearly, quarterly bisphosphonates yielded significantly greater BMD gains, compared with weekly bisphosphonate groups (p<0.05). In addition, patients receiving 70 mg weekly alendronate+vitamin D3 had greater gains in BMD than alendronate Single preparation (p<0.05). Conclusion: Bisphosphonates yielded significantly greater BMD gains than SERM. Of the bisphosphonates, the changes from baseline in BMD of yearly, quarterly IV bisphosphonates yielded significantly greater BMD gains, compared with weekly oral bisphosphonate groups. In addition, vitamin D3 plays an significant role in BMD gains.
Keywords
Osteoporosis; Osteopenia; SERM; Bisphosphonate; Raloxifene; Alendronate;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause 2006; 13(3): 340-67.   DOI   ScienceOn
2 Hamdy RC, Petak SM, Lenchik L. Which central dual Xray absorptiometry skeletal sites and regions of interest should be used to determine the diagnosis of osteoporosis? J Clin Densitom 2002; 5: S11-8.   DOI   ScienceOn
3 Kim DY. Clinical Application of Bone Mineral Density Measurement. Nucl Med Mol Imaging 2004; 38(4): 275-81.
4 K JM. The Understanding of Osteoporosis. Drug Information 2005; 31(8): 2-6.
5 Nancy E. Lane. Epidemiology, etiology, and diagnosis of osteoporosis, American Journal of Obstetrics and Gynecology 2006; 194: 3-11.   DOI   ScienceOn
6 Study of an Osteoporosis Management Program in Korea. Korean Health Promotion Foundation & Ministry of Health and Welfare. 2007
7 Small RE. Uses and Limitations of Bone Mineral Density Measurements in the Management of Osteoporosis. Med Gen Med 2005; 7(2): 3.
8 Lenchik L, Leib ES, Hamdy RC, et al. Executive summary International Society for Clinical Densitometry position development conference. J Clin Densitom 2002; 5: S1-3.   DOI   ScienceOn
9 Lash RW, Nicholson JM, Velez L, et al. Diagnosis and Management of Osteoporosis. Prim Care 2009; 36(1): 181-98.   DOI   ScienceOn
10 Analysis of the health care situation in Korea. Korea Ministry of Health and Welfare, 2008
11 Chung KH, Oh YH, Seok JE, et al. Study the needs of the elderly living conditions and welfare of Korean society in 2004 (Policy Report No.. 2005-03 of Korea Institute for Health and Social Affairs, 2005; 1-192).
12 Choi JY, Han SH, Shin AS, et al. Prevalence and Risk Factors of Osteoporosis and Osteopenia in Korean Women: Cross-sectional Study. J Menopausal Med 2008; 14(1): 35-49
13 Prevalence of osteoporosis research, to be conducted at the national level. Centers for Disease Control Press Release 2008
14 Yoon SH, Kim JG. Current treatment of postmenopausal osteoporosis. Korean J Obstet Gynecol 2005; 48(4): 844-56.
15 Lewiecki EM. Prevention and treatment of postmenopausal osteoporosis. Obstet Gynecol Clin North Am 2008; 35(2): 301-15.   DOI   ScienceOn
16 Clinician's Guide to Prevention and Treatment of Osteoporosis National Osteoporosis Foundation. 2008, p19-26.
17 Kang BM. Comparison of Anti-osteoporotic Medications and Alternatives. Obstet Gynecol Sci 2006; 49(12): 2459-73.
18 Physician's Guideline for Osteoporosis. Korean Society for Bone and Mineral Research. 2007
19 Vestergaard P. Anti-resorptive therapy for the prevention of postmenopausal osteoporosis: when should treatment begin? Treat Endocrinol 2005; 4(5): 263-77.   DOI   ScienceOn
20 NIH Consensus Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285: 785-95.   DOI   ScienceOn
21 Tosteson AN, Burge RT, Marshall DA, et al. Therapies for Treatment of Osteoporosis in US Women: Cost-effectiveness and Budget Impact Considerations. Am J Manag Care 2008; 14(9): 605-15.
22 Rakel & Bope. Conn's Current Therapy. 2008; 60th ed.: Chapter 149